Journal
LIVER INTERNATIONAL
Volume 41, Issue 9, Pages 1999-2008Publisher
WILEY
DOI: 10.1111/liv.15013
Keywords
biomarkers; clinical trials; liver cirrhosis; metabolic associated fatty liver disease (MAFLD); portal hypertension; portal pressure
Categories
Funding
- Boehringer Ingelheim
Ask authors/readers for more resources
This paper discusses the challenges and opportunities in drug development for patients with non-alcoholic steatohepatitis cirrhosis, emphasizing the need for individualized therapeutic regimens based on specific cirrhosis substages and treatment mechanisms. Understanding the probabilistic expectations for different outcomes at each substage is crucial for selecting appropriate therapeutic strategies.
Non-alcoholic steatohepatitis has emerged as a major public health problem, and the burden of non-alcoholic steatohepatitis cirrhosis is projected to increase by 64%-156% by 2030. The threat is aggravated by the fact that are currently no approved drugs for the treatment of non-alcoholic steatohepatitis. In this paper, we review the main challenges to drug development in patients with non-alcoholic steatohepatitis cirrhosis, and describe the opportunities brought by the advances in the understanding of the clinical and pathophysiological nuances of cirrhosis. The design of therapeutic regimens for non-alcoholic steatohepatitis cirrhosis will vary according to the specific cirrhosis substage (compensated vs decompensated), and the specific mechanistic basis of therapy, targeted either at improving aetiology-specific pathways and/or at more general aetiology-agnostic processes. The understanding of the probabilistic expectations for the whole range of potential outcomes, rooted at different mechanistic drivers at each specific substage, will be essential in order to choose adequate estimands and therapeutic strategies for clinical trials and individual patients with non-alcoholic steatohepatitis cirrhosis. Finally, we provide a summary of the main pitfalls and uncertainties in the design of clinical trials for non-alcoholic steatohepatitis cirrhosis and discuss potential biomarkers for use in trials and practice for these patients.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available